Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases.
Adenoma
/ drug therapy
Combined Modality Therapy
Drug Administration Schedule
Female
Humans
Japan
Male
Middle Aged
Peptides, Cyclic
/ administration & dosage
Pituitary Neoplasms
/ drug therapy
Preoperative Period
Somatostatin
/ administration & dosage
Thyrotrophs
/ drug effects
Thyrotropin
/ metabolism
Treatment Outcome
Journal
Neuro endocrinology letters
ISSN: 2354-4716
Titre abrégé: Neuro Endocrinol Lett
Pays: Sweden
ID NLM: 8008373
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
10
2019
accepted:
12
03
2020
pubmed:
28
4
2020
medline:
26
8
2021
entrez:
28
4
2020
Statut:
ppublish
Résumé
Case 1 was a 51-year-old man diagnosed with thyrotropin (TSH)-secreting pituitary tumor. The octreotide loading test showed suppression of TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. Three months after treatment initiation, tumor shrinkage was observed, and pituitary tumor resection was performed through transsphenoidal surgery. Case 2 was a 47-year-old woman in whom the octreotide loading test showed suppressed TSH secretion. Treatment with lanreotide preoperatively at 90 mg/month resulted in normalization of thyroid function. After six months of treatment, tumor reduction was observed, and transsphenoidal surgery was performed. In both cases, lanreotide administration before TSH-secreting pituitary tumor resection achieved normalization of thyroid function and tumor shrinkage. Treatment with lanreotide seems effective in patients who show TSH secretion suppression in the octreotide loading test.
Substances chimiques
Peptides, Cyclic
0
lanreotide
0G3DE8943Y
Somatostatin
51110-01-1
Thyrotropin
9002-71-5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM